Compared to interferon beta-1a, the reduction of grey matter volume loss was greater in those treated with both doses of the oral S1P receptor modulator across all age groups, including the youngest patients at the highest risk for brain volume loss.
The senior preclinical and clinical imaging scientist at the National Institute of Neurological Disorders and Stroke spoke about the potential of the central vein sign to help improve the time to an accurate diagnosis in MS.

SAP Partner Banner

About NeurologyLive's Multiple Sclerosis Clinical Focus page:

The NeurologyLive Multiple Sclerosis Clinical Focus center offers the latest clinical news and expert insights related to this disabling disease of the central nervous system (CNS). Content found here includes video interviews with multiple sclerosis experts and key opinion leaders in neurology sharing insights on new and emerging therapies and management techniques, including insight and perspective novel treatment techniques. 

This page offers information regarding current strategies for multiple sclerosis treatment, as well as emerging therapeutic options for the disease being presented at major medical conferences and gaining traction in the scientific literature.